A Review of the Role of Silodosin as Medical Expulsive Therapy for Ureteral Stones
Keywords:
Ureteral Stone Expulsion, Urolithiasis, alpha-1 adrenoceptor blocker, Silodosin, Tamsulosin
Abstract
Urolithiasis is a chronic human condition that has immense public health importance and it poses a tremendous economic burden on our society. Medical expulsive therapy (MET) for the treatment of ureteral stones has emerged as a cost-effective approach. In the last few years, a number of drugs have been introduced and used successfully as MET for the expulsion of small, uncomplicated ureteral calculi. Using a selective α-adrenoceptor blocker for MET has emerged as an effective treatment approach and is widely used for ureteral stones. Silodosin, a selective α-blocker, has a higher selectivity for the α1A receptor as compared to other agents in the class. The objective of this review is to determine the efficacy and safety of Silodosin in MET as compared to placebo and Tamsulosin.
Conflict of Interest: The authors are full time employees of Aristo Pharmaceuticals Private Limited, Mumbai, India.
Source of Support: None declared.
References
1. Yang D, Wu J, Yuan H, Cui Y. The efficacy and safety of silodosin for the treatment of ureteral stones: a systematic review and meta-analysis. BMC Urol. 2016;16 (23):1-8.
2. Huang W, Xue p, Zong H, Zhang Y. Efficacy and safety of silodosin in the medical expulsion therapy for distal ureteral calculi: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016 Jan;81(1):13-22.
3. Liu Y, Chen Y, Liao B, Luo D, Wang K, Li H, Zeng G. Epidemiology of urolithiasis in Asia. Asian J Urol. 2018;5:205 - 14.
4. Kumar S, Kumar J, Agrawal MM, Singh SK, Agrawal S, Parmar KM. Role of tamsulosin, tadalafil, and silodosin as the medical expulsive therapy in lower ureteric stone: a randomized trial (a pilot study). Urology 2015;85(1):59-63.
5. Gupta S, Lodh B, Singh AK, Somarendra K, Meitei KS, Singh SR. Comparing the efficacy of tamsulosin and silodosin in the medical expulsion therapy for ureteral calculi. J Clin Diagn Res. 2013 Aug;7(8):1672-74.
6. Campschroer T, Zhu X, Vernooij RWM, Lock MTWT. Alphablockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev. 2018 Apr 5;4(4):CD008509.
7. Dell’Atti L. Silodosin versus tamsulosin as medical expulsive therapy for distal ureteral stones: a prospective randomized study. Urologia 2015;82(1):54-57.
8. Bos D, Kapoor A. Update on medical expulsive therapy for distal ureteral stones: beyond alpha-blockers. Can Urol Assoc J 2014;8(11-12):442-5.
9. Lipkin M, Shah O. The use of alpha-blockers for the treatment of nephrolithiasis. Rev Urol. 2006;8(suppl 4):35-42
10. Malin JM, Deane RF, Boyarsky S. Characterisation of adrenergic receptors in human ureter. Br J Urol. 1970;42:171-174.
11. Hanno PM, Wein AJ, Malkowicz B. Penn Clinical Manual of Urology. 1st ed. Philadelphia: Saunders – Elsevier; 2007. 507p.
12. Sigala S, Dellabella M, Milanese G, Fornari S, Faccoli S, Palazzolo F, Peroni A, Mirabella G, Cunico SC, Spano P, Muzzonigro G. Evidence for the presence of alpha1 adrenoceptor subtypes in the human ureter. Neurourol Urodyn. 2005;24(2):142-8.
13. Itoh Y, Kojima Y, Yasui T, Tozawa K, Sasaki S, Kohri K. Examination of alpha 1 adrenoceptor subtypes in the human ureter. Int J Urol. 2007;14: 749–53.
14. Tomiyama Y, Kobayashi K, Tadachi M, Kobayashi S, Inada Y, Kobayashi M, Yamazaki Y. Expressions and mechanical functions of alpha1- adrenoceptor subtypes in hamster ureter. Eur J Pharmacol. 2007 Nov 14;573(1-3):201-5.
15. Bagot K, Chess-Williams R. Alpha(1A/L)-adrenoceptors mediate contraction of the circular smooth muscle of the pig urethra. Auton Autacoid Pharmacol. 2006 Oct;26(4):345-53.
16. Sasaki S, Tomiyama Y, Kobayashi S, Kojima Y, Kubota Y, Kohri K. Characterization of α1-adrenoceptor subtypes mediating contraction in human isolated ureters. Urology. 2011 Mar;77(3):762.e13-7.
17. McCune DF, Edelmann SE, Olges JR, Post GR, Waldrop BA, Waugh DJJ, Perez DM, Piascik MT. Regulation of the cellular localization and signaling properties of the α1B - and α1A -adrenoceptors by agonists and inverse agonists. Mol Pharmacol. 2000 Apr; 57(4): 659-66.
18. Chalothorn D, McCune DF, Edelmann SE, García-Cazarín ML, Tsujimoto G, Piascik MT. Differences in the cellular localization and agonist- mediated internalization properties of the alpha(1)-adrenoceptor subtypes. Mol Pharmacol. 2002 May;61(5):1008-16.
19. Tsuzaka Y, Matsushima H, Kaneko T, Yamaguchi T, Homma Y. Naftopidil vs silodosin in medical expulsive therapy for ureteral stones: a randomized controlled study in Japanese male patients. Int J Urol. 2011; 18: 792–95.
20. Sridharan K, Sivaramakrishnan G. Medical expulsive therapy in urolithiasis: a mixed treatment comparison network meta-analysis of randomized controlled clinical trials. Expert Opin Pharmacother. 2017 Oct;18(14):1421-31.
21. Cervenàkov I, J Fillo J, Mardiak J, Kopecný M, Smirala J, Lepies P. Speedy elimination of ureterolithiasis in lower part of ureters with the alpha 1-blocker - amsulosin. Int J Nephrol Urol. 2002; 34: 25–29.
22. Dellabella M, Milanese G, Muzzonigro G. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol. 2003;170:2202–5.
23. Resim S, Ekerbicer H, Ciftci A. Effect of tamsulosin on the number and intensity of ureteral colic in patients with lower ureteral calculus. Int J Urol. 2005; 12:615–20.
24. Sio MD, Autorino R, Lorenzo GD, Damiano R, Giordano D, Cosentino L, Pane U, Giacomo FD, Mordente S, D’Armiento M. Medical expulsive treatment of distal- ureteral stones using tamsulosin: a single-center experience. J Endourol. 2006 Jan;20(1):12-6.
25. Yilmaz E, Batislam E, Basar MM, Tuglu D, Ferhat M, Basar H. The comparison and efficacy of 3 different alpha1- adrenergic blockers for distal ureteral stones. J Urol. 2005 Jun;173(6):2010-2.
26. Porpiglia F, Ghignone G, Fiori C, Fontana D, Scarpa RM. Nifedipine versus tamsulosin for the Management of Lower Ureteral Stones. J Urol. 2004 Aug;172(2):568-71.
27. Dellabella M, Milanese G, Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinolin medical expulsive therapy for distal ureteral calculi. J Urol. 2005 Jul;174(1):167-72.
28. Itoh Y, Okada A, Yasui T, Hamamoto S, Hirose M, Kojima Y, Tozawa K, Sasaki S, Kohri K. Efficacy of selective α1A adrenoceptor antagonist silodosin in the medical expulsive therapy for ureteral stones. Int J Urol. 2011;18:672–74.
29. Sur RL, Shore N, L’Esperance J, Knudsen B, Gupta M, Olsen S, Shah O. Silodosin to facilitate passage of ureteral stones: a multi-institutional, randomized, double-blinded, placebocontrolled trial. Eur Urol . 2015 May;67(5):959-64.
30. Keating GM. Silodosin: A review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia. Drugs.2015;75:207–17.
31. Tatemichi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N. α1- adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi. 2006 Mar;126:209-16.
32. Martin DJ. Preclinical pharmacology of α1-adrenoceptor antagonists. Eur Urol 1999;36(suppl 1):35–41.
33. Elgalaly H, Sakr A, Fawzi A, Salem EA, Desoky E, Shahin A, Kamel M. Silodosin vs tamsulosin in the management of distal ureteric stones: A prospective randomised study. Arab J Urol. 2016; 14: 12–17.
34. Imperatore V, Fusco F, Creta M, Meo SD, Buonopane R, Longo N, Imbimbo C, Mirone V. Medical expulsive therapy for distal ureteric stones: tamsulosin versus silodosin. Arch Ital Urol Androl. 2014 Jun 30;86(2):103-7.
35. Itoh Y, Okada A, Yasui T, Ando R, Tozawa K, Sasaki S, Kohri K. Administration of the selective alpha 1A-adrenoceptor antagonist silodosin facilitates expulsion of size 5–10 mm distal ureteral stones, as compared to control. Int Urol Nephrol. 2013; 45:675–78.
36. Gharib T, Mohey A, Fathi A, Alhefnawy M, Alazaby H, Eldakhakhny A. Comparative study between silodosin and tamsulosin in expectant therapy of distal ureteral stones. Urol Int. 2018;101(2):161-66.
37. Wang CJ, Tsai P, Chang CH. Efficacy of silodosin in expulsive therapy for distal ureteral stones: a randomized doubleblinded controlled trial. Urol J. 2016 Jun 28;13(3):2666-71.
38. Hsu YP, Hsu CW, Bai CH, Cheng SW, Chen KC, Chen C. Silodosin versus tamsulosin for medical expulsive treatment of ureteral stones: A systematic review and meta-analysis. PLoS One. 2018 Aug 28;13(8):1-24.
2. Huang W, Xue p, Zong H, Zhang Y. Efficacy and safety of silodosin in the medical expulsion therapy for distal ureteral calculi: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016 Jan;81(1):13-22.
3. Liu Y, Chen Y, Liao B, Luo D, Wang K, Li H, Zeng G. Epidemiology of urolithiasis in Asia. Asian J Urol. 2018;5:205 - 14.
4. Kumar S, Kumar J, Agrawal MM, Singh SK, Agrawal S, Parmar KM. Role of tamsulosin, tadalafil, and silodosin as the medical expulsive therapy in lower ureteric stone: a randomized trial (a pilot study). Urology 2015;85(1):59-63.
5. Gupta S, Lodh B, Singh AK, Somarendra K, Meitei KS, Singh SR. Comparing the efficacy of tamsulosin and silodosin in the medical expulsion therapy for ureteral calculi. J Clin Diagn Res. 2013 Aug;7(8):1672-74.
6. Campschroer T, Zhu X, Vernooij RWM, Lock MTWT. Alphablockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev. 2018 Apr 5;4(4):CD008509.
7. Dell’Atti L. Silodosin versus tamsulosin as medical expulsive therapy for distal ureteral stones: a prospective randomized study. Urologia 2015;82(1):54-57.
8. Bos D, Kapoor A. Update on medical expulsive therapy for distal ureteral stones: beyond alpha-blockers. Can Urol Assoc J 2014;8(11-12):442-5.
9. Lipkin M, Shah O. The use of alpha-blockers for the treatment of nephrolithiasis. Rev Urol. 2006;8(suppl 4):35-42
10. Malin JM, Deane RF, Boyarsky S. Characterisation of adrenergic receptors in human ureter. Br J Urol. 1970;42:171-174.
11. Hanno PM, Wein AJ, Malkowicz B. Penn Clinical Manual of Urology. 1st ed. Philadelphia: Saunders – Elsevier; 2007. 507p.
12. Sigala S, Dellabella M, Milanese G, Fornari S, Faccoli S, Palazzolo F, Peroni A, Mirabella G, Cunico SC, Spano P, Muzzonigro G. Evidence for the presence of alpha1 adrenoceptor subtypes in the human ureter. Neurourol Urodyn. 2005;24(2):142-8.
13. Itoh Y, Kojima Y, Yasui T, Tozawa K, Sasaki S, Kohri K. Examination of alpha 1 adrenoceptor subtypes in the human ureter. Int J Urol. 2007;14: 749–53.
14. Tomiyama Y, Kobayashi K, Tadachi M, Kobayashi S, Inada Y, Kobayashi M, Yamazaki Y. Expressions and mechanical functions of alpha1- adrenoceptor subtypes in hamster ureter. Eur J Pharmacol. 2007 Nov 14;573(1-3):201-5.
15. Bagot K, Chess-Williams R. Alpha(1A/L)-adrenoceptors mediate contraction of the circular smooth muscle of the pig urethra. Auton Autacoid Pharmacol. 2006 Oct;26(4):345-53.
16. Sasaki S, Tomiyama Y, Kobayashi S, Kojima Y, Kubota Y, Kohri K. Characterization of α1-adrenoceptor subtypes mediating contraction in human isolated ureters. Urology. 2011 Mar;77(3):762.e13-7.
17. McCune DF, Edelmann SE, Olges JR, Post GR, Waldrop BA, Waugh DJJ, Perez DM, Piascik MT. Regulation of the cellular localization and signaling properties of the α1B - and α1A -adrenoceptors by agonists and inverse agonists. Mol Pharmacol. 2000 Apr; 57(4): 659-66.
18. Chalothorn D, McCune DF, Edelmann SE, García-Cazarín ML, Tsujimoto G, Piascik MT. Differences in the cellular localization and agonist- mediated internalization properties of the alpha(1)-adrenoceptor subtypes. Mol Pharmacol. 2002 May;61(5):1008-16.
19. Tsuzaka Y, Matsushima H, Kaneko T, Yamaguchi T, Homma Y. Naftopidil vs silodosin in medical expulsive therapy for ureteral stones: a randomized controlled study in Japanese male patients. Int J Urol. 2011; 18: 792–95.
20. Sridharan K, Sivaramakrishnan G. Medical expulsive therapy in urolithiasis: a mixed treatment comparison network meta-analysis of randomized controlled clinical trials. Expert Opin Pharmacother. 2017 Oct;18(14):1421-31.
21. Cervenàkov I, J Fillo J, Mardiak J, Kopecný M, Smirala J, Lepies P. Speedy elimination of ureterolithiasis in lower part of ureters with the alpha 1-blocker - amsulosin. Int J Nephrol Urol. 2002; 34: 25–29.
22. Dellabella M, Milanese G, Muzzonigro G. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol. 2003;170:2202–5.
23. Resim S, Ekerbicer H, Ciftci A. Effect of tamsulosin on the number and intensity of ureteral colic in patients with lower ureteral calculus. Int J Urol. 2005; 12:615–20.
24. Sio MD, Autorino R, Lorenzo GD, Damiano R, Giordano D, Cosentino L, Pane U, Giacomo FD, Mordente S, D’Armiento M. Medical expulsive treatment of distal- ureteral stones using tamsulosin: a single-center experience. J Endourol. 2006 Jan;20(1):12-6.
25. Yilmaz E, Batislam E, Basar MM, Tuglu D, Ferhat M, Basar H. The comparison and efficacy of 3 different alpha1- adrenergic blockers for distal ureteral stones. J Urol. 2005 Jun;173(6):2010-2.
26. Porpiglia F, Ghignone G, Fiori C, Fontana D, Scarpa RM. Nifedipine versus tamsulosin for the Management of Lower Ureteral Stones. J Urol. 2004 Aug;172(2):568-71.
27. Dellabella M, Milanese G, Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinolin medical expulsive therapy for distal ureteral calculi. J Urol. 2005 Jul;174(1):167-72.
28. Itoh Y, Okada A, Yasui T, Hamamoto S, Hirose M, Kojima Y, Tozawa K, Sasaki S, Kohri K. Efficacy of selective α1A adrenoceptor antagonist silodosin in the medical expulsive therapy for ureteral stones. Int J Urol. 2011;18:672–74.
29. Sur RL, Shore N, L’Esperance J, Knudsen B, Gupta M, Olsen S, Shah O. Silodosin to facilitate passage of ureteral stones: a multi-institutional, randomized, double-blinded, placebocontrolled trial. Eur Urol . 2015 May;67(5):959-64.
30. Keating GM. Silodosin: A review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia. Drugs.2015;75:207–17.
31. Tatemichi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N. α1- adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi. 2006 Mar;126:209-16.
32. Martin DJ. Preclinical pharmacology of α1-adrenoceptor antagonists. Eur Urol 1999;36(suppl 1):35–41.
33. Elgalaly H, Sakr A, Fawzi A, Salem EA, Desoky E, Shahin A, Kamel M. Silodosin vs tamsulosin in the management of distal ureteric stones: A prospective randomised study. Arab J Urol. 2016; 14: 12–17.
34. Imperatore V, Fusco F, Creta M, Meo SD, Buonopane R, Longo N, Imbimbo C, Mirone V. Medical expulsive therapy for distal ureteric stones: tamsulosin versus silodosin. Arch Ital Urol Androl. 2014 Jun 30;86(2):103-7.
35. Itoh Y, Okada A, Yasui T, Ando R, Tozawa K, Sasaki S, Kohri K. Administration of the selective alpha 1A-adrenoceptor antagonist silodosin facilitates expulsion of size 5–10 mm distal ureteral stones, as compared to control. Int Urol Nephrol. 2013; 45:675–78.
36. Gharib T, Mohey A, Fathi A, Alhefnawy M, Alazaby H, Eldakhakhny A. Comparative study between silodosin and tamsulosin in expectant therapy of distal ureteral stones. Urol Int. 2018;101(2):161-66.
37. Wang CJ, Tsai P, Chang CH. Efficacy of silodosin in expulsive therapy for distal ureteral stones: a randomized doubleblinded controlled trial. Urol J. 2016 Jun 28;13(3):2666-71.
38. Hsu YP, Hsu CW, Bai CH, Cheng SW, Chen KC, Chen C. Silodosin versus tamsulosin for medical expulsive treatment of ureteral stones: A systematic review and meta-analysis. PLoS One. 2018 Aug 28;13(8):1-24.
Published
2020-09-28
How to Cite
Dr. Manish Maladkar, Srividya Sankar, Sudhir Awate. (2020). A Review of the Role of Silodosin as Medical Expulsive Therapy for Ureteral Stones. The Indian Practitioner, 73(9), 25-32. Retrieved from https://articles.theindianpractitioner.com/index.php/tip/article/view/1051
Section
Review article
